Filing Flows › Stoke Therapeutics (STOK) › Q1 2025
Stoke Therapeutics (STOK) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
Stoke Therapeutics (STOK) reported revenue of $159M for the first quarter 2025 (Q1 2025), up 38-fold from a year earlier and +601% from the quarter before. Operating margin was 70.2%, net earnings $113M (71.2% of revenue).
Stoke Therapeutics, Q1 2025: revenue $159M (38× year over year), operating margin 70.2%, net earnings $113M, operating cash flow $132M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $159M | +601% | 38× |
| Operating profit | $111M | — | — |
| Net earnings | $113M | — | — |
| Operating cash flow | $132M | — | — |
| Free cash flow | $132M | — | — |
What changed
Revenue was $158.6M in Q1 2025, up 3661% year over year and up 601% from the previous quarter.
Operating profit was $111.2M, a 70.2% margin (up 743.1 points year over year). Total costs grew 45% against revenue growth of 3661%. The fastest-growing cost line was Research & development (+46%). Net earnings were $112.9M. The effective tax rate was 1.1%.
Operating cash flow was $131.8M, 117% of net earnings. Non-cash charges added back $477K of depreciation and $6.8M of share-based compensation. Working capital and other items added $11.7M. Capital expenditures of $152K left free cash flow of $131.7M.
Questions
What was Stoke Therapeutics' revenue in the first quarter 2025?
Stoke Therapeutics (STOK) reported revenue of $159M for the first quarter 2025 (Q1 2025), up 38-fold from a year earlier and +601% from the quarter before.
Was Stoke Therapeutics profitable in the first quarter 2025?
Operating profit was $111M (70.2% of revenue) and net earnings $113M.
Source: Stoke Therapeutics 10-Q on SEC EDGAR.